The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,314K data for 602K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

47 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

Article Title
p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones.EBI
Merck & Co.
p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.EBI
Merck Research Laboratories
Potent inhibitors of the MAP kinase p38.EBI
R. W. Johnson Pharmaceutical Research Institute
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.EBI
SmithKline Beecham Pharmaceuticals Ltd
Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.EBI
Sejong University
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.EBI
Eli Lilly and Company
Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.EBI
Translational Research Institute
Inhibitors of c-Jun N-terminal kinases: an update.EBI
Eberhard Karls Universit£t T£bingen
SAR156497, an exquisitely selective inhibitor of aurora kinases.EBI
Kinase inhibitors: not just for kinases anymore.EBI
Northwestern University
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.EBI
Millennium Pharmaceuticals Inc
Pyridazine based inhibitors of p38 MAPK.EBI
Merck Research Laboratories
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.EBI
Bayer Research Center
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.EBI
Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.EBI
Abbott Bioresearch Center
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.EBI
Boehringer Ingelheim Pharmaceuticals Inc
Imidazopyrimidines, potent inhibitors of p38 MAP kinase.EBI
Johnson & Johnson Pharmaceutical Research and Development LLC
Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.EBI
Merck Research Laboratories
Structure-guided optimization of a novel class of ASK1 inhibitors with increased spEBI
Takeda Research in California
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.EBI
Merck Research Laboratories
Substituted imidazoles as glucagon receptor antagonists.EBI
Merck Research Laboratories
Design and molecular modeling of novel P38? MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.EBI
National Research Centre
Chemical Space of DNA-Encoded Libraries.EBI
University of Utah
Progress in the development of more effective and safer analgesics for pain management.EBI
University of Catania
Pyrroles and other heterocycles as inhibitors of p38 kinase.EBI
Merck Research Laboratory
Why Some Targets Benefit from beyond Rule of Five Drugs.EBI
Boston University
Synthesis and molecular docking studies of new furochromone derivatives as p38? MAPK inhibitors targeting human breast cancer MCF-7 cells.EBI
Cairo University
KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.EBI
VU University Amsterdam
Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.EBI
The Scripps Research Institute
The identification of novel p38? isoform selective kinase inhibitors having an unprecedented p38? binding mode.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
High-content single-cell drug screening with phosphospecific flow cytometry.EBI
Stanford University
Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: a new use of silicon bioisosteres in medicinal chemistry.EBI
Paradigm Therapeutics Ltd
Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.EBI
Eberhard-Karls-University T£bingen
p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold.EBI
Merck Research Laboratories
The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.EBI
Procter and Gamble Pharmaceuticals
Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.EBI
Procter and Gamble Pharmaceuticals
Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.EBI
Eberhard-Karls-University T£bingen
From imidazoles to pyrimidines: new inhibitors of cytokine release.EBI
Eberhard-Karls-University T£bingen
An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.EBI
Aventis Pharma S.A.
Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system.EBI
Vertex Pharmaceuticals Inc
Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.EBI
Takeda Pharmaceutical Company Limited
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.EBI
Novartis Institutes for Biomedical Research
Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer.EBI
University of Zagreb